News & Updates

Patients with idiopathic pulmonary fibrosis (IPF) who have high exposure to nitrogen dioxide (NO2) are at greater risk of disease progression, suggests a recent study.

Breathing exercise devices such as a conventional threshold loading training (TLT) device or an innovative respiratory training (IRT) device, when used in combination with lower torso sports training (LTST), proved beneficial in improving pulmonary function, exercise capacity, and quality of life (QoL) in individuals with asthma, a study suggests. However, IRT trumped TLT in terms of improvements in some respiratory and physical performance variables.

Long-term exposure to low levels of multiple air pollutants is associated with increased risks of depression and anxiety, a population-based study has shown.

Individuals with long-term exposure to air pollutants appear to be at higher risk of pneumonia, with the risk being more pronounced among smokers, as shown in a study.

Early administration of oral VV116 was noninferior to nirmatrelvir-ritonavir in shortening the time to sustained clinical recovery in individuals with mild-to-moderate COVID-19 who were at high risk for progression to severe disease, a phase III trial has shown. VV116 also had fewer safety issues than nirmatrelvir-ritonavir.

Treatment with the combination of gefitinib and chemotherapy appears to yield significant increases in progression-free survival (PFS), intracranial PFS, and overall survival in patients with untreated EGFR-mutant non-small cell lung cancer (NSCLC) brain metastases as compared gefitinib monotherapy, according to the results of the phase III GAP BRAIN study.

Children diagnosed with asthma between ages 5 and 7 years may have an increased risk of developing type 1 diabetes (T1D) and inflammatory bowel diseases (IBD; Crohn’s disease and ulcerative colitis), a Danish nationwide registry study suggests.

Lung cancer screening based on a risk model is more cost-effective than the 2021 recommendation by the US Preventive Services Task Force (USPSTF), meriting further consideration for the former, reports a recent study.

Individuals with rifampin-resistant tuberculosis (RR-TB) may have the option to undergo shorter treatment periods, as findings from the phase II/III TB-PRACTECAL* trial show the noninferiority and superiority of a 24-week, all-oral regimen to standard of care (SoC). It also had a better safety profile than SoC.